Patents by Inventor Mehdi Arbabi-Ghahroudi
Mehdi Arbabi-Ghahroudi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250000976Abstract: Herein are provided anti-BCMA single domain antibodies (sdAb) prepared byte immunizing a llama with the ecto-domain of human B-cell maturation antigen (BCMA) that is preferentially expressed by mature B lymphocytes. By constructing a library of the heavy chain repertoire generated, VHH antibodies specific to the immunogen were isolated. The 13 unique example antibodies initially produced comprise CDR1, CDR2, and CDR3 sequences corresponding, respectively to SEQ NOs: 1-3, 4-6, 7-9, 10-12, 13-15, 16-18, 19-21, 22-24, 25-27, 28-30, 31-33, 34-36, 37-39; and related sequences. Also provided are multivalent antibodies comprising any one of the sdAbs, including bispecific T-cell engagers, bispecific killer cell engagers (BiKEs), and trispecific killer cell engagers (TriKEs). Also described are chimeric antigen receptors (CARs) for CAR-T therapy comprising any one of the aforementioned sdAbs.Type: ApplicationFiled: October 5, 2022Publication date: January 2, 2025Inventors: Mehdi ARBABI-GHAHROUDI, Risini WEERATNA, Scott MCCOMB, Cunle WU
-
Publication number: 20240156870Abstract: Herein are provided anti-EGFR single domain antibodies (sdAb) prepared by immunizing a llama with recombinant human EGFRvIII. VHH antibodies specific to EGFR were isolated. The example antibodies initially produced comprise CDR1, CDR2, and CDR3 sequences corresponding, respectively to SEQ NOs: 1-3, 4-6, 7-9, 10-12, 13-15, 16-18, 19-21, 22-24, 25-27, 28-30, 31-33, 34-36, 37-39, 40-42, 43-45, and 46-48; and related sequences, including humanized variants. Also provided are multivalent antibodies comprising any one of the sdAbs, including bispecific T-cell engagers, bispecific killer cell engagers (BiKEs), and trispecific killer cell engagers (TriKEs). Also described are chimeric antigen receptors (CARs) for CAR-T therapy comprising any one of the aforementioned sdAbs. Uses of these molecules in the treatment of cancer are also described, in particularly EGFR-high cancers. Hinge lengths may be selected to achieve desired activities, such as high activity or high selectivity for target vs. non-target cells.Type: ApplicationFiled: October 28, 2021Publication date: May 16, 2024Inventors: Kevin HENRY, Martin ROSSOTTI, Mehdi ARBABI-GHAHROUDI, Scott MCCOMB, Risini WEERATNA, Jamshid TANHA
-
Patent number: 11945858Abstract: The present disclosure concerns antibodies specific for the Na v.7 polypeptides which are capable of antagonizing the biological activity of the Na v.7 polypeptide. The anti-Na v.7 antibodies can be used for alleviating the symptoms of pain and/or for treating or alleviating the symptoms of an hyperproliferative disease. The presence disclosure also concerns immunogens and methods for making antibodies, such as the anti-Na v.7 antibodies, comprising a single-domain antibody.Type: GrantFiled: May 17, 2019Date of Patent: April 2, 2024Assignee: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Marzia Martina, Balu Chakravarthy, Yves Durocher, Mehdi Arbabi-Ghahroudi, Anne Marcil, Danica Stanimirovic, Traian Sulea, Maria Moreno, Umberto Banderali
-
Publication number: 20240076406Abstract: The present disclosure relates to a single domain antibody that specifically binds to the epitope in the catalytic domain of carbonic anhydrase IX (CA-IX). The single domain antibody has a dissociation constant (KD) of 1×10?7 or lower for a monomeric form of human CA-IX and/or a dimeric form of human CA-IX.Type: ApplicationFiled: January 21, 2022Publication date: March 7, 2024Applicant: National Research Council of CanadaInventors: Anne EG LENFERINK, Mehdi ARBABI GHAHROUDI, Nazanin ROHANI LARIJANI, Scott MCCOMB
-
Publication number: 20230265185Abstract: Herein are provided anti-CD22 single domain antibodies (sdAb) prepared by immunizing a llama with the extracellular domain of the predominant human CD22 isoform. By constructing a library of the heavy chain repertoire generated, VHH antibodies specific to the immunogen were isolated. The 27 example antibodies initially produced comprise CDR1, CDR2, and CDR3 sequences corresponding, respectively to SEQNOs: 1-3, 4-6, 7-9, 10-12, 13-15, 16- 18, 19-21, 22-24, 25-27, 28-30, 31-33, 34-36, 37-39, 40-42, 43-45, 46-48, 49-51, 52-54, 55- 57, 58-60, 61-63, 64-66, 67-69, 70-72, 73-75, 75-78, and 79-81; and related sequences. Also provided are multivalent antibodies comprising any one of the sdAbs, including bispecific T-cell engagers, bispecific killer cell engagers (BiKEs), and trispecific killer cell engagers (TriKEs). Also described are chimeric antigen receptors (CARs) for CAR-T therapy comprising any one of the aforementioned sdAbs. Uses of these molecules in the treatment of cancer are also described.Type: ApplicationFiled: July 27, 2021Publication date: August 24, 2023Inventors: Scott MCCOMB, Risini WEERATNA, Mehdi ARBABI-GHAHROUDI, Tina NGUYEN, Cunle WU
-
Publication number: 20210206842Abstract: The present disclosure concerns antibodies specific for the Na v.7 polypeptides which are capable of antagonizing the biological activity of the Na v.7 polypeptide. The anti-Na v.7 antibodies can be used for alleviating the symptoms of pain and/or for treating or alleviating the symptoms of an hyperproliferative disease. The presence disclosure also concerns immunogens and methods for making antibodies, such as the anti-Na v.7 antibodies, comprising a single-domain antibody.Type: ApplicationFiled: May 17, 2019Publication date: July 8, 2021Inventors: Marzia MARTINA, Balu CHAKRAVARTHY, Yves DUROCHER, Mehdi ARBABI-GHAHROUDI, Anne MARCIL, Danica STANIMIROVIC, Traian SULEA, Maria MORENO, Umberto BANDERALI
-
Patent number: 10259864Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.Type: GrantFiled: December 20, 2017Date of Patent: April 16, 2019Assignee: National Research Council of CanadaInventors: Mehdi Arbabi Ghahroudi, Ali Riazi, Christine M. Szymanski, Greg Hussack, Jamshid Tanha, Roger MacKenzie
-
Patent number: 10112998Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF 1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF 1R polypeptide. Humanized forms of the camelid VHH are also generated.Type: GrantFiled: December 4, 2014Date of Patent: October 30, 2018Assignee: National Research Council of CanadaInventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
-
Patent number: 10106614Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Daltons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF1R polypeptide. Humanized forms of the camelid VHH are also generated.Type: GrantFiled: December 4, 2014Date of Patent: October 23, 2018Assignee: National Research Council of CanadaInventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
-
Patent number: 10100117Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF 1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF 1R polypeptide. Humanized forms of the camelid VHH are also generated.Type: GrantFiled: December 4, 2014Date of Patent: October 16, 2018Assignee: National Research Council of CanadaInventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
-
Patent number: 10098973Abstract: The present invention relates to Tau-specific antibodies, fragments thereof, and uses thereof. More specifically, the present invention relates to Tau-specific antibodies, fragments thereof, and conjugates thereof with conjugated to a superparamagnetic nanoparticle. The molecules of the present invention may be used in visualizing damage from traumatic brain injury.Type: GrantFiled: October 6, 2015Date of Patent: October 16, 2018Assignee: National Research Council of CanadaInventors: Garnette R. Sutherland, Sanju Lama, Mehdi Arbabi-Ghahroudi
-
Publication number: 20180142000Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.Type: ApplicationFiled: December 20, 2017Publication date: May 24, 2018Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Mehdi ARBABI GHAHROUDI, Ali RIAZI, Christine M. SZYMANSKI, Greg HUSSACK, Jamshid TANHA, Roger MACKENZIE
-
Publication number: 20180134769Abstract: The present invention is directed to Clostridium difficile toxin-specific antibodies, compositions, and uses thereof. The anti-toxin antibodies may be specific for either TcdA or TcdB. The invention also includes methods of treating a Clostridium difficile infection, methods of capturing Clostridium difficile toxins, and methods of detecting Clostridium difficile toxins.Type: ApplicationFiled: September 22, 2017Publication date: May 17, 2018Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Greg HUSSACK, Mehdi ARBABI-GHAHROUDI, Roger MACKENZIE, Jamshid TANHA
-
Patent number: 9926363Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.Type: GrantFiled: October 24, 2013Date of Patent: March 27, 2018Assignee: National Research Council of CanadaInventors: Mehdi Arbabi Ghahroudi, Ali Riazi, Christine M. Szymanski, Greg Hussack, Jamshid Tanha, Roger MacKenzie
-
Publication number: 20170296680Abstract: The present invention relates to Tau-specific antibodies, fragments thereof, and uses thereof. More specifically, the present invention relates to Tau-specific antibodies, fragments thereof, and conjugates thereof with conjugated to a superparamagnetic nanoparticle. The molecules of the present invention may be used in visualizing damage from traumatic brain injury.Type: ApplicationFiled: October 6, 2015Publication date: October 19, 2017Applicant: National Research Council of CanadaInventors: Garnette R. SUTHERLAND, Sanju LAMA, Mehdi ARBABI-GHAHROUDI
-
Publication number: 20170022277Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF 1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF 1R polypeptide. Humanized forms of the camelid VHH are also generated.Type: ApplicationFiled: December 4, 2014Publication date: January 26, 2017Applicant: National Research Council of CanadaInventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
-
Publication number: 20170015749Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Daltons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF1R polypeptide. Humanized forms of the camelid VHH are also generated.Type: ApplicationFiled: December 4, 2014Publication date: January 19, 2017Applicant: National Research Council of CanadaInventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
-
Publication number: 20170015748Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF 1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF 1R polypeptide. Humanized forms of the camelid VHH are also generated.Type: ApplicationFiled: December 4, 2014Publication date: January 19, 2017Applicant: National Research Council of CanadaInventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
-
Publication number: 20150307597Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.Type: ApplicationFiled: October 24, 2013Publication date: October 29, 2015Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Mehdi ARBABI GHAHROUDI, Ali RIAZI, Christine M. SZYMANSKI, Greg HUSSACK, Jamshid TANHA, Roger MACKENZIE
-
Patent number: 8623369Abstract: Anti-ICAM-1 VHH single-domain antibodies (sdAbs) are generated by immunizing a llama with recombinant ICAM-1. These antibodies are linked to an imaging moiety for in vivo or ex vivo imaging of ICAM-1-related pathological conditions including atherosclerotic plaques. The antibodies may also be linked to a therapeutic agent to specifically target and treat ICAM-1-related pathological conditions.Type: GrantFiled: April 27, 2011Date of Patent: January 7, 2014Assignee: National Research Council of CanadaInventors: Abedelnasser Abulrob, Mehdi Arbabi-Ghahroudi, Danica Stanimirovic